Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

BACKGROUND: Our previous survey on first-in-human trials (FIHT) of monoclonal antibodies (mAbs) showed that, due to their limited toxicity, the recommended phase II dose (RP2D) was only tentatively defined. METHODS: We identified, by MEDLINE search, articles on single-agent trials of mAbs with an FI...

Descripción completa

Detalles Bibliográficos
Autores principales: Viala, Marie, Vinches, Marie, Alexandre, Marie, Mollevi, Caroline, Durigova, Anna, Hayaoui, Nadia, Homicsko, Krisztian, Cuenant, Alice, Gongora, Céline, Gianni, Luca, Tosi, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846071/
https://www.ncbi.nlm.nih.gov/pubmed/29438365
http://dx.doi.org/10.1038/bjc.2017.473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846071/
https://www.ncbi.nlm.nih.gov/pubmed/29438365
http://dx.doi.org/10.1038/bjc.2017.473

Ejemplares similares